Innate Pharma Announces Voting Results of 2026 Annual General Meeting

Innate Pharma S.A. announced the results of its 2026 Annual General Meeting (AGM) held on May 21, 2026, in Marseille, France. The company reported that all proposed resolutions were successfully voted upon during the meeting. A total of 34,921,313 voting rights were represented, achieving a quorum of 37.136%. While specific details regarding individual resolutions were not listed in the summary text, the company confirmed that documentation regarding the results and a recording of the meeting would be made available on its corporate website. Innate Pharma continues to focus on its clinical-stage pipeline, including IPH4502 (a Nectin-4 ADC), lacutamab (anti-KIR3DL2), and monalizumab (anti-NKG2A), the latter of which is being developed in collaboration with AstraZeneca. The filing also notes the involvement of CEO Jonathan Dickinson in the signing of the report. No new clinical data or financial guidance was provided in this specific governance-focused update.